Autoimmunity Diagnostics Market - Global Forecast To 2031
商品番号 : SMB-83879
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 299 |
| 図表数 | 369 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本調査レポートは、自己免疫疾患診断市場を製品別（消耗品および機器）、検査タイプ別（ルーチン検査、炎症検査、自己抗体および免疫学的検査、尿検査、その他の検査）、疾患タイプ別（全身性自己免疫疾患および臓器特異的自己免疫疾患）、エンドユーザー別（臨床検査室、病院・診療所、その他のエンドユーザー）、地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）に分類しています。レポートは、自己免疫疾患診断市場の成長に影響を与える推進要因、制約要因、機会、課題など、主要な要因に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、ソリューション、主要戦略、買収、契約に関する洞察が得られています。自己免疫疾患診断市場に関連する新製品の発売や最近の動向についても解説しています。本レポートは、自己免疫疾患診断市場エコシステムにおける新興企業の競合分析も網羅しています。
自己免疫疾患診断市場は、2025年の55億7,000万米ドルから2031年には89億8,000万米ドルに達し、予測期間中は年平均成長率（CAGR）8.3%で成長すると予測されています。この成長は、自己免疫疾患の有病率の上昇、早期診断への意識の高まり、そしてマルチプレックス免疫測定やバイオマーカーを用いた検査といった技術の進歩によって牽引されています。さらに、自動化プラットフォームの導入拡大と政府の支援策も、検査件数の増加と診断精度の向上に貢献しています。
The autoimmune disease diagnosis market is projected to reach USD 8.98 billion by 2031 from USD 5.57 billion in 2025, at a CAGR of 8.3% during the forecast period. This growth is driven by the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and technological advancements such as multiplex immunoassays and biomarker-based tests. Additionally, the growing adoption of automated platforms and supportive government initiatives contribute to increased testing volumes and improved diagnostic accuracy.
By disease type, the systemic autoimmune diseases segment accounted for the largest market share in 2024.
Based on disease type, the global autoimmune disease diagnosis market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. The systemic autoimmune diseases segment accounted for the largest market share in 2024. The large share of this region is attributed to the widespread prevalence of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. These diseases typically affect multiple organs and systems, necessitating frequent and comprehensive diagnostic evaluations. The complexity of diagnosis, reliance on advanced immunological tests, and the need for continuous disease monitoring drive higher demand for diagnostic solutions in this segment.
By end user, the clinical laboratories segment accounted for the largest market share during the forecast period.
Based on end users, the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals & clinics, and other end users. Among these, the clinical laboratories segment accounted for the largest market share owing to specialized expertise, advanced diagnostic technologies, and high-throughput capabilities. Equipped with automated platforms such as ELISA, chemiluminescence, and immunofluorescence, these laboratories can perform complex tests with high accuracy and efficiency. Their role as centralized testing hubs allows them to process large sample volumes at reduced per-test costs.
Asia Pacific: The fastest-growing region in the autoimmune disease diagnosis market during the forecast period.
The autoimmune disease diagnosis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the region is primarily driven by the rising prevalence of autoimmune diseases, increasing healthcare expenditure, the growing adoption of advanced diagnostic technologies, and heightened awareness about early disease detection across emerging economies. Additionally, improvements in healthcare infrastructure and supportive government initiatives further contribute to market expansion in the Asia Pacific region.
The break-up of the profile of primary participants in the autoimmune disease diagnosis market:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
- By Region: North America – 51%, Europe – 21%, the Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa- 4%
The key players in the market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Grifols S.A. (Spain), Werfen S.A. (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Exagen Inc. (US), Trinity Biotech plc (Ireland), Tecan Group Ltd. (Switzerland), Danaher Corporation (US), BIOSYNEX SA (France), QuidelOrtho Corporation (US), Revvity, Inc. (US), bioMérieux SA (France), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), SD Biosensor, INC. (Korea), Cambridge Life Sciences Ltd (UK), A. Menarini Diagnostics s.r.l (Italy), Sebia (France), KRONUS (US), Erba Group (Czech Republic), AESKU.GROUP GmbH (Germany), Medsource Ozone Biomedicals Pvt. Ltd. (India), and Epitope Diagnostics Inc. (US).
Research Coverage:
This research report categorizes the autoimmune disease diagnosis market by product (consumables and instruments), by test type (routine laboratory tests, inflammatory tests, autoantibodies and immunologic tests, urinalysis tests, and other tests), by disease type (systemic autoimmune diseases and organ-specific autoimmune diseases), by end user (clinical laboratories, hospitals & clinics, and other end users), and by region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the autoimmune disease diagnosis market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the autoimmune disease diagnosis market. This report covers the competitive analysis of upcoming startups in the autoimmune disease diagnosis market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall autoimmune disease diagnosis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (High incidence of autoimmune diseases, rising awareness related to early disease diagnosis, growing number of r&d activities for innovative diagnostic solutions, advancements in diagnostic technologies), restraints (high capital requirements), opportunities (utilization of biosensors for autoimmune disease diagnosis, growth potential of emerging economies, growing number of reagent rental agreements), and challenges (complexities associated with diagnosis of autoimmune diseases, shortage of skilled professionals) influencing the growth of the autoimmune disease diagnosis market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the autoimmune disease diagnosis market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the autoimmune disease diagnosis market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoimmune disease diagnosis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Revvity, Inc. (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany).
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 MARKETS COVERED & REGIONAL SCOPE 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 KEY STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key secondary sources 34
2.1.1.2 Key data from secondary sources 35
2.1.2 PRIMARY RESEARCH 36
2.1.2.1 Key primary sources 36
2.1.2.2 Key data from primary sources 37
2.1.2.3 Key industry insights 38
2.2 MARKET SIZE ESTIMATION 39
2.2.1 BOTTOM-UP APPROACH 39
2.2.1.1 Approach 1: Company revenue estimation approach 40
2.2.1.2 Approach 2: Presentations of companies and primary interviews 40
2.2.1.3 Growth forecast 41
2.2.1.4 CAGR projections 41
2.2.2 TOP-DOWN APPROACH 41
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43
2.4 MARKET SHARE ASSESSMENT 43
2.5 RESEARCH ASSUMPTIONS 44
2.5.1 PARAMETRIC ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 44
2.7 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 AUTOIMMUNITY DIAGNOSTICS MARKET OVERVIEW 50
4.2 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2031 51
4.3 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2031 51
4.4 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2031 52
4.5 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2031 52
4.6 AUTOIMMUNITY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 High incidence of autoimmune diseases 55
5.2.1.2 Rising awareness related to early disease diagnosis 56
5.2.1.3 Increasing number of R&D activities for innovative diagnostic solutions 56
5.2.1.4 Advancements in diagnostic technologies 57
5.2.2 RESTRAINTS 58
5.2.2.1 High capital requirements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Utilization of biosensors for autoimmune disease diagnosis 59
5.2.3.2 Growth potential of emerging economies 59
5.2.3.3 Growing number of reagent rental agreements 60
5.2.4 CHALLENGES 60
5.2.4.1 Complexities associated with diagnosis of autoimmune diseases 60
5.2.4.2 Shortage of skilled professionals 60
5.3 PRICING ANALYSIS 61
5.3.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT, 2023−2025 61
5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023−2025 61
5.3.3 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023−2025 62
5.4 PATENT ANALYSIS 63
5.4.1 LIST OF MAJOR PATENTS 64
5.5 VALUE CHAIN ANALYSIS 64
5.6 SUPPLY CHAIN ANALYSIS 66
5.7 TRADE ANALYSIS 67
5.7.1 IMPORT DATA (HS CODE 3822) 67
5.7.2 EXPORT DATA (HS CODE 3822) 68
5.8 ECOSYSTEM ANALYSIS 68
5.8.1 ROLE IN ECOSYSTEM 69
5.9 PORTER’S FIVE FORCES ANALYSIS 69
5.9.1 THREAT OF NEW ENTRANTS 71
5.9.2 THREAT OF SUBSTITUTES 71
5.9.3 BARGAINING POWER OF BUYERS 71
5.9.4 BARGAINING POWER OF SUPPLIERS 71
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 71
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
5.10.2 BUYING CRITERIA 73
5.10.3 REGULATORY LANDSCAPE 73
5.10.3.1 North America 73
5.10.3.1.1 US 73
5.10.3.1.2 Canada 74
5.10.3.2 Europe 74
5.10.3.2.1 Germany 75
5.10.3.2.2 UK 75
5.10.3.2.3 France 75
5.10.3.2.4 Italy 75
5.10.3.3 Asia Pacific 76
5.10.3.3.1 China 76
5.10.3.3.2 Japan 76
5.10.3.3.3 India 76
5.10.3.3.4 Australia 77
5.10.3.4 Latin America 77
5.10.3.5 Middle East 77
5.10.3.5.1 Africa 78
5.10.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.11 TECHNOLOGY ANALYSIS 80
5.11.1 KEY TECHNOLOGIES 80
5.11.1.1 Immunoassays 80
5.11.2 COMPLEMENTARY TECHNOLOGIES 81
5.11.2.1 Flow cytometry 81
5.12 KEY CONFERENCES & EVENTS, 2025–2026 82
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
5.14 INVESTMENT & FUNDING SCENARIO 84
5.15 CASE STUDY ANALYSIS 84
5.15.1 CASE STUDY 1: LABORATORY-BASED DIAGNOSIS OF
SYSTEMIC LUPUS ERYTHEMATOSUS 84
5.15.2 CASE STUDY 2: DIAGNOSTIC IMPORTANCE OF AUTOANTIBODY TESTING IN IDENTIFICATION OF LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) 85
5.16 IMPACT OF AI/GENERATIVE AI ON AUTOIMMUNITY DIAGNOSTICS MARKET 85
5.16.1 INTRODUCTION 85
5.16.2 MARKET POTENTIAL OF AI 86
5.16.3 AI USE CASES 86
5.16.4 IMPLEMENTATION OF AI, BY KEY COMPANY AND CASE 87
5.16.5 FUTURE OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET 87
5.17 TRUMP TARIFF IMPACT ON AUTOIMMUNITY DIAGNOSTICS MARKET 87
5.17.1 INTRODUCTION 87
5.17.2 KEY TARIFF RATES 88
5.17.3 PRICE IMPACT ANALYSIS 89
5.17.4 KEY IMPACT ON COUNTRY/REGION 89
5.17.4.1 North America 89
5.17.4.2 Europe 89
5.17.4.3 Asia Pacific 89
5.17.5 IMPACT ON END-USE INDUSTRIES 89
5.17.5.1 Clinical laboratories 90
5.17.5.2 Hospitals & clinics 90
6 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT 91
6.1 INTRODUCTION 92
6.2 CONSUMABLES 92
6.2.1 RECURRING PURCHASE FOR HIGH VOLUME OF DIAGNOSTIC TESTING TO PROPEL MARKET 92
6.3 INSTRUMENTS 95
6.3.1 GROWING NEED FOR AUTOMATION AND HIGH-THROUGHPUT TESTING TO DRIVE MARKET 95
7 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE 98
7.1 INTRODUCTION 99
7.2 AUTOANTIBODIES AND IMMUNOLOGIC TESTS 99
7.2.1 ACCURATE DETECTION & MONITORING ABILITIES FOR BROAD APPLICATIONS TO PROPEL MARKET 99
7.3 ROUTINE LABORATORY TESTS 102
7.3.1 RECURRENT TESTING DUE TO COST EFFICIENCY TO BOOST DEMAND 102
7.4 INFLAMMATORY TESTS 104
7.4.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES TO DRIVE MARKET 104
7.5 URINALYSIS TESTS 106
7.5.1 TECHNOLOGICAL ADVANCEMENTS IN URINE ANALYZERS TO FUEL UPTAKE 106
7.6 OTHER TESTS 108
8 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE 110
8.1 INTRODUCTION 111
8.2 SYSTEMIC AUTOIMMUNE DISEASES 111
8.2.1 RHEUMATOID ARTHRITIS 114
8.2.1.1 Uptake of rheumatoid factor immunological test to boost demand 114
8.2.2 SYSTEMIC LUPUS ERYTHEMATOSUS 116
8.2.2.1 Utilization of autoimmune testing kits for constant monitoring to propel market 116
8.2.3 PSORIASIS 119
8.2.3.1 Frequent association with systemic inflammation and comorbidities to boost demand 119
8.2.4 MULTIPLE SCLEROSIS 121
8.2.4.1 Public-private investments for MS awareness to fuel market 121
8.2.5 OTHER SYSTEMIC AUTOIMMUNE DISEASES 123
8.3 ORGAN-SPECIFIC AUTOIMMUNE DISEASES 125
8.3.1 TYPE-1 DIABETES 128
8.3.1.1 Rising global incidence among children & adults to fuel market 128
8.3.2 CELIAC DISEASE 131
8.3.2.1 Growing awareness regarding gluten sensitivity and improved testing availability to drive market 131
8.3.3 INFLAMMATORY BOWEL DISEASE 133
8.3.3.1 Growing awareness of chronic gastrointestinal autoimmune disorders to fuel market 133
8.3.4 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES 135
9 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER 138
9.1 INTRODUCTION 139
9.2 CLINICAL LABORATORIES 139
9.2.1 ABILITY TO CONDUCT HIGH VOLUME OF SPECIALIZED TESTS TO PROPEL MARKET 139
9.3 HOSPITALS & CLINICS 141
9.3.1 GROWING AWARENESS OF EARLY DISEASE DIAGNOSIS TO FUEL UPTAKE 141
9.4 OTHER END USERS 144
10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION 146
10.1 INTRODUCTION 147
10.2 NORTH AMERICA 147
10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 148
10.2.2 US 152
10.2.2.1 High healthcare expenditure and expansive research initiatives for product commercialization to boost demand 152
10.2.3 CANADA 156
10.2.3.1 Rising prevalence of chronic autoimmune conditions to drive market 156
10.3 EUROPE 159
10.3.1 EUROPE: MACROECONOMIC OUTLOOK 160
10.3.2 UK 163
10.3.2.1 Growing R&D efforts for early disease diagnosis to fuel uptake 163
10.3.3 GERMANY 166
10.3.3.1 Increasing incidence of multiple sclerosis to drive market 166
10.3.4 FRANCE 169
10.3.4.1 Expansion of lab modernization to support market growth 169
10.3.5 ITALY 172
10.3.5.1 Growing disease burden and aging demographics to fuel market 172
10.3.6 SPAIN 175
10.3.6.1 Prevalence of celiac disease to drive market 175
10.3.7 REST OF EUROPE 178
10.4 ASIA PACIFIC 181
10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 181
10.4.2 CHINA 187
10.4.2.1 Government initiatives for early autoimmune disease screening to fuel market 187
10.4.3 JAPAN 190
10.4.3.1 Rapidly aging population and advanced healthcare infrastructure to boost demand 190
10.4.4 INDIA 193
10.4.4.1 Government-led healthcare initiatives and rapid expansion of diagnostic infrastructure to propel market 193
10.4.5 AUSTRALIA 196
10.4.5.1 Increasing incidences of autoimmune diseases to support market growth 196
10.4.6 REST OF ASIA PACIFIC 199
10.5 LATIN AMERICA 202
10.5.1 INCREASING INCIDENCE OF TYPE-1 DIABETES TO FUEL MARKET 202
10.5.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 203
10.6 MIDDLE EAST & AFRICA 206
10.6.1 FAVORABLE GOVERNMENT INITIATIVES FOR EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH 206
10.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 207
11 COMPETITIVE LANDSCAPE 211
11.1 INTRODUCTION 211
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 211
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET 211
11.3 REVENUE ANALYSIS, 2022−2024 213
11.4 MARKET SHARE ANALYSIS, 2024 214
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 216
11.5.1 STARS 216
11.5.2 EMERGING LEADERS 216
11.5.3 PERVASIVE PLAYERS 216
11.5.4 PARTICIPANTS 216
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 218
11.5.5.1 Company footprint 218
11.5.5.2 Region footprint 218
11.5.5.3 Product footprint 219
11.5.5.4 Test type footprint 219
11.5.5.5 Disease type footprint 220
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 220
11.6.1 PROGRESSIVE COMPANIES 220
11.6.2 RESPONSIVE COMPANIES 221
11.6.3 DYNAMIC COMPANIES 221
11.6.4 STARTING BLOCKS 221
11.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 222
11.6.5.1 Detailed list of key startups/SMEs 222
11.6.5.2 Competitive benchmarking of startups/SMEs 222
11.7 COMPANY VALUATION & FINANCIAL METRICS 223
11.7.1 FINANCIAL METRICS 223
11.7.2 COMPANY VALUATION 224
11.8 BRAND/PRODUCT COMPARISON 224
11.9 COMPETITIVE SCENARIO 225
11.9.1 PRODUCT LAUNCHES & APPROVALS 225
11.9.2 DEALS 225
11.9.3 EXPANSIONS 226
11.9.4 OTHER DEVELOPMENTS 226
12 COMPANY PROFILES 227
12.1 KEY PLAYERS 227
12.1.1 F. HOFFMANN-LA ROCHE LTD. 227
12.1.1.1 Business overview 227
12.1.1.2 Products offered 228
12.1.1.3 MnM view 229
12.1.1.3.1 Key strengths 229
12.1.1.3.2 Strategic choices 229
12.1.1.3.3 Weaknesses & competitive threats 229
12.1.2 ABBOTT LABORATORIES 230
12.1.2.1 Business overview 230
12.1.2.2 Products offered 231
12.1.2.3 MnM view 232
12.1.2.3.1 Key strengths 232
12.1.2.3.2 Strategic choices 232
12.1.2.3.3 Weaknesses & competitive threats 232
12.1.3 REVVITY, INC. 233
12.1.3.1 Business overview 233
12.1.3.2 Products offered 234
12.1.3.3 Recent developments 236
12.1.3.3.1 Product launches 236
12.1.3.4 MnM view 237
12.1.3.4.1 Key strengths 237
12.1.3.4.2 Strategic choices 237
12.1.3.4.3 Weaknesses & competitive threats 237
12.1.4 THERMO FISHER SCIENTIFIC INC. 238
12.1.4.1 Business overview 238
12.1.4.2 Products offered 239
12.1.4.3 Recent developments 240
12.1.4.3.1 Product launches 240
12.1.4.3.2 Deals 241
12.1.4.3.3 Other developments 241
12.1.4.4 MnM view 241
12.1.4.4.1 Key strengths 241
12.1.4.4.2 Strategic choices 242
12.1.4.4.3 Weaknesses & competitive threats 242
12.1.5 SIEMENS HEALTHINEERS AG 243
12.1.5.1 Business overview 243
12.1.5.2 Products offered 244
12.1.5.3 Recent developments 245
12.1.5.3.1 Product approvals 245
12.1.5.3.2 Deals 246
12.1.5.4 MnM view 246
12.1.5.4.1 Key strengths 246
12.1.5.4.2 Strategic choices 246
12.1.5.4.3 Weaknesses & competitive threats 247
12.1.6 BIO-RAD LABORATORIES, INC. 248
12.1.6.1 Business overview 248
12.1.6.2 Products offered 249
12.1.7 GRIFOLS S.A. 251
12.1.7.1 Business overview 251
12.1.7.2 Products offered 252
12.1.7.3 Recent developments 253
12.1.7.3.1 Deals 253
12.1.8 WERFEN S.A. 254
12.1.8.1 Business overview 254
12.1.8.2 Products offered 255
12.1.8.3 Recent developments 257
12.1.8.3.1 Product approvals 257
12.1.9 EXAGEN INC. 258
12.1.9.1 Business overview 258
12.1.9.2 Products offered 259
12.1.9.3 Recent developments 260
12.1.9.3.1 Product launches 260
12.1.9.3.2 Deals 260
12.1.10 TRINITY BIOTECH PLC 261
12.1.10.1 Business overview 261
12.1.10.2 Products offered 263
12.1.11 TECAN GROUP LTD. 264
12.1.11.1 Business overview 264
12.1.11.2 Products offered 265
12.1.12 DANAHER CORPORATION 267
12.1.12.1 Business overview 267
12.1.12.2 Products offered 269
12.1.12.3 Recent developments 269
12.1.12.3.1 Deals 269
12.1.13 BIOSYNEX SA 270
12.1.13.1 Business overview 270
12.1.13.2 Products offered 271
12.1.13.3 Recent developments 272
12.1.13.3.1 Deals 272
12.1.14 QUIDELORTHO CORPORATION 273
12.1.14.1 Business overview 273
12.1.14.2 Products offered 274
12.1.14.3 Recent developments 275
12.1.14.3.1 Expansions 275
12.1.15 BIOMÉRIEUX SA 276
12.1.15.1 Business overview 276
12.1.15.2 Products offered 277
12.1.16 DIASORIN S.P.A. 278
12.1.16.1 Business overview 278
12.1.16.2 Products offered 280
12.1.16.3 Recent developments 280
12.1.16.3.1 Deals 280
12.2 OTHER PLAYERS 281
12.2.1 BECTON, DICKINSON AND COMPANY 281
12.2.2 SD BIOSENSOR, INC. 282
12.2.3 CAMBRIDGE LIFE SCIENCES LTD 283
12.2.4 A. MENARINI DIAGNOSTICS S.R.L 284
12.2.5 SEBIA 285
12.2.6 KRONUS 286
12.2.7 ERBA GROUP 287
12.2.8 AESKU.GROUP GMBH 288
12.2.9 MEDSOURCE OZONE BIOMEDICALS PVT. LTD. 289
12.2.10 EPITOPE DIAGNOSTICS INC. 290
13 APPENDIX 291
13.1 DISCUSSION GUIDE 291
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 295
13.3 CUSTOMIZATION OPTIONS 297
13.4 RELATED REPORTS 297
13.5 AUTHOR DETAILS 298
LIST OF TABLES
TABLE 1 AUTOIMMUNITY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 37
TABLE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 45
TABLE 3 NIH-FUNDED INVESTMENTS & GRANTS, BY DISEASE TYPE 57
TABLE 4 A FEW RECENT EXAMPLES OF INNOVATIONS IN AUTOIMMUNE DIAGNOSTIC TECHNOLOGIES ARE LISTED BELOW: 58
TABLE 5 INDICATIVE SELLING PRICING TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, 2023–2025 61
TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAYS, BY KEY PLAYER, 2023–2025 61
TABLE 7 INDICATIVE SELLING PRICE TREND OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS, BY REGION, 2023–2025 62
TABLE 8 AUTOIMMUNITY DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023–2024 64
TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 67
TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 68
TABLE 11 AUTOIMMUNITY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 69
TABLE 12 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOIMMUNITY DIAGNOSTICS PRODUCTS (%) 72
TABLE 14 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 73
TABLE 15 CLASSIFICATION OF IVD DEVICES IN EUROPE 74
TABLE 16 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 76
TABLE 17 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 18 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 19 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 20 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 21 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 22 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 82
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 88
TABLE 24 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 92
TABLE 25 KEY COMPANIES OFFERING CONSUMABLES 93
TABLE 26 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION,
2023–2031 (USD MILLION) 93
TABLE 27 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES,
BY COUNTRY, 2023–2031 (USD MILLION) 94
TABLE 28 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES,
BY COUNTRY, 2023–2031 (USD MILLION) 94
TABLE 29 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CONSUMABLES,
BY COUNTRY, 2023–2031 (USD MILLION) 94
TABLE 30 KEY COMPANIES OFFERING INSTRUMENTS 96
TABLE 31 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2023–2031 (USD MILLION) 96
TABLE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2031 (USD MILLION) 96
TABLE 33 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2031 (USD MILLION) 97
TABLE 34 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2031 (USD MILLION) 97
TABLE 35 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 99
TABLE 36 AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY REGION, 2023–2031 (USD MILLION) 101
TABLE 37 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 101
TABLE 38 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 101
TABLE 39 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 102
TABLE 40 AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS,
BY REGION, 2023–2031 (USD MILLION) 103
TABLE 41 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 103
TABLE 42 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 103
TABLE 43 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR ROUTINE LABORATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 104
TABLE 44 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY REGION, 2023–2031 (USD MILLION) 105
TABLE 45 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 105
TABLE 46 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS,
BY COUNTRY, 2023–2031 (USD MILLION) 105
TABLE 47 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 106
TABLE 48 AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY REGION, 2023–2031 (USD MILLION) 107
TABLE 49 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 107
TABLE 50 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS,
BY COUNTRY, 2023–2031 (USD MILLION) 107
TABLE 51 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR URINALYSIS TESTS,
BY COUNTRY, 2023–2031 (USD MILLION) 108
TABLE 52 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY REGION,
2023–2031 (USD MILLION) 108
TABLE 53 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS,
BY COUNTRY, 2023–2031 (USD MILLION) 109
TABLE 54 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS, BY COUNTRY, 2023–2031 (USD MILLION) 109
TABLE 55 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER TESTS,
BY COUNTRY, 2023–2031 (USD MILLION) 109
TABLE 56 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 111
TABLE 57 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE,
2023–2031 (USD MILLION) 112
TABLE 58 SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION,
2023–2031 (USD MILLION) 112
TABLE 59 NORTH AMERICA: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113
TABLE 60 EUROPE: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 113
TABLE 61 ASIA PACIFIC: SYSTEMIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 113
TABLE 62 KEY COMPANIES CURRENTLY OFFERING RHEUMATOID ARTHRITIS PRODUCTS 115
TABLE 63 AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2023–2031 (USD MILLION) 115
TABLE 64 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2031 (USD MILLION) 115
TABLE 65 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS,
BY COUNTRY, 2023–2031 (USD MILLION) 116
TABLE 66 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2031 (USD MILLION) 116
TABLE 67 KEY COMPANIES CURRENTLY OFFERING SYSTEMIC LUPUS
ERYTHEMATOSUS PRODUCTS 117
TABLE 68 AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2023–2031 (USD MILLION) 117
TABLE 69 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118
TABLE 70 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118
TABLE 71 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2023–2031 (USD MILLION) 118
TABLE 72 AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY REGION,
2023–2031 (USD MILLION) 119
TABLE 73 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS,
BY COUNTRY, 2023–2031 (USD MILLION) 120
TABLE 74 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS, BY COUNTRY, 2023–2031 (USD MILLION) 120
TABLE 75 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR PSORIASIS,
BY COUNTRY, 2023–2031 (USD MILLION) 120
TABLE 76 KEY COMPANIES CURRENTLY OFFERING MULTIPLE SCLEROSIS PRODUCTS 121
TABLE 77 AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2023–2031 (USD MILLION) 122
TABLE 78 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2031 (USD MILLION) 122
TABLE 79 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS,
BY COUNTRY, 2023–2031 (USD MILLION) 122
TABLE 80 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2031 (USD MILLION) 123
TABLE 81 KEY COMPANIES CURRENTLY OFFERING OTHER SYSTEMIC AUTOIMMUNE
DISEASE PRODUCTS 124
TABLE 82 OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY REGION,
2023–2031 (USD MILLION) 124
TABLE 83 NORTH AMERICA: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 124
TABLE 84 EUROPE: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 125
TABLE 85 ASIA PACIFIC: OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 125
TABLE 86 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY TYPE,
2023–2031 (USD MILLION) 126
TABLE 87 ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION,
2023–2031 (USD MILLION) 127
TABLE 88 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 127
TABLE 89 EUROPE: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 127
TABLE 90 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 128
TABLE 91 NUMBER OF PEOPLE LIVING WITH TYPE 1 DIABETES, 2024 129
TABLE 92 KEY COMPANIES CURRENTLY OFFERING TYPE 1 DIABETES PRODUCTS 129
TABLE 93 AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES, BY REGION,
2023–2031 (USD MILLION) 129
TABLE 94 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE
1 DIABETES, BY COUNTRY, 2023–2031 (USD MILLION) 130
TABLE 95 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES,
BY COUNTRY, 2023–2031 (USD MILLION) 130
TABLE 96 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR TYPE 1 DIABETES,
BY COUNTRY, 2023–2031 (USD MILLION) 130
TABLE 97 KEY COMPANIES OFFERING CELIAC DISEASE PRODUCTS 131
TABLE 98 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE, BY REGION,
2023–2031 (USD MILLION) 132
TABLE 99 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE,
BY COUNTRY, 2023–2031 (USD MILLION) 132
TABLE 100 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE,
BY COUNTRY, 2023–2031 (USD MILLION) 132
TABLE 101 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CELIAC DISEASE,
BY COUNTRY, 2023–2031 (USD MILLION) 133
TABLE 102 KEY COMPANIES OFFERING INFLAMMATORY BOWEL DISEASE PRODUCTS 133
TABLE 103 AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE,
BY REGION, 2023–2031 (USD MILLION) 134
TABLE 104 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 134
TABLE 105 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 134
TABLE 106 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR INFLAMMATORY
BOWEL DISEASE, BY COUNTRY, 2023–2031 (USD MILLION) 135
TABLE 107 KEY COMPANIES CURRENTLY OFFERING OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE PRODUCTS 136
TABLE 108 OTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSIS MARKET,
BY REGION, 2023–2031 (USD MILLION) 136
TABLE 109 NORTH AMERICA: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 136
TABLE 110 EUROPE: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 137
TABLE 111 ASIA PACIFIC: OTHER ORGAN-SPECIFIC AUTOIMMUNITY DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2031 (USD MILLION) 137
TABLE 112 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 139
TABLE 113 AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY REGION, 2023–2031 (USD MILLION) 140
TABLE 114 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 140
TABLE 115 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2023–2031 (USD MILLION) 141
TABLE 116 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 141
TABLE 117 NUMBER OF HOSPITALS, BY COUNTRY, 2023 142
TABLE 118 AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2031 (USD MILLION) 142
TABLE 119 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 120 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 121 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 122 AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION) 144
TABLE 123 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 144
TABLE 124 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 145
TABLE 125 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 145
TABLE 126 AUTOIMMUNITY DIAGNOSTICS MARET, BY REGION, 2023–2031 (USD MILLION) 147
TABLE 127 NORTH AMERICA: MACROECONOMIC INDICATORS 148
TABLE 128 NORTH AMERICA: NUMBER OF RHEUMATOID ARTHRITIS (RA) CASES,
BY COUNTRY, 2023–2031 149
TABLE 129 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 150
TABLE 130 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 150
TABLE 131 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 150
TABLE 132 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 151
TABLE 133 NORTH AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 151
TABLE 134 NORTH AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET,
BY TYPE, 2023–2031 (USD MILLION) 152
TABLE 135 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 152
TABLE 136 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 153
TABLE 137 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 154
TABLE 138 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 154
TABLE 139 US: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 155
TABLE 140 US: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 155
TABLE 141 US: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 155
TABLE 142 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 156
TABLE 143 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 157
TABLE 144 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 157
TABLE 145 CANADA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 158
TABLE 146 CANADA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 158
TABLE 147 CANADA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 159
TABLE 148 EUROPE: MACROECONOMIC INDICATORS 160
TABLE 149 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 160
TABLE 150 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 161
TABLE 151 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 161
TABLE 152 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 161
TABLE 153 EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 162
TABLE 154 EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 162
TABLE 155 EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 163
TABLE 156 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 164
TABLE 157 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 164
TABLE 158 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 164
TABLE 159 UK: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 165
TABLE 160 UK: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 165
TABLE 161 UK: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 165
TABLE 162 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 166
TABLE 163 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 167
TABLE 164 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 167
TABLE 165 GERMANY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 168
TABLE 166 GERMANY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 168
TABLE 167 GERMANY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 169
TABLE 168 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 170
TABLE 169 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 170
TABLE 170 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 170
TABLE 171 FRANCE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 171
TABLE 172 FRANCE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 171
TABLE 173 FRANCE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 172
TABLE 174 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 173
TABLE 175 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 173
TABLE 176 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 173
TABLE 177 ITALY: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 174
TABLE 178 ITALY: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 174
TABLE 179 ITALY: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 174
TABLE 180 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 175
TABLE 181 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 176
TABLE 182 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 176
TABLE 183 SPAIN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 177
TABLE 184 SPAIN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 177
TABLE 185 SPAIN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 178
TABLE 186 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 179
TABLE 187 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 179
TABLE 188 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 179
TABLE 189 REST OF EUROPE: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 180
TABLE 190 REST OF EUROPE: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 180
TABLE 191 REST OF EUROPE: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 181
TABLE 192 ASIA PACIFIC: MACROECONOMIC INDICATORS 182
TABLE 193 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 184
TABLE 194 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 184
TABLE 195 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 185
TABLE 196 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 185
TABLE 197 ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 186
TABLE 198 ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 186
TABLE 199 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 187
TABLE 200 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 188
TABLE 201 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 188
TABLE 202 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 188
TABLE 203 CHINA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 189
TABLE 204 CHINA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 189
TABLE 205 CHINA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 190
TABLE 206 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 191
TABLE 207 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 191
TABLE 208 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 191
TABLE 209 JAPAN: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 192
TABLE 210 JAPAN: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 192
TABLE 211 JAPAN: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 193
TABLE 212 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 194
TABLE 213 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 194
TABLE 214 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 195
TABLE 215 INDIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 195
TABLE 216 INDIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 196
TABLE 217 INDIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 196
TABLE 218 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 197
TABLE 219 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 197
TABLE 220 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 198
TABLE 221 AUSTRALIA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 198
TABLE 222 AUSTRALIA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 199
TABLE 223 AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 199
TABLE 224 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 200
TABLE 225 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 200
TABLE 226 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 201
TABLE 227 REST OF ASIA PACIFIC: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 201
TABLE 228 REST OF ASIA PACIFIC: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET,
BY TYPE, 2023–2031 (USD MILLION) 202
TABLE 229 REST OF ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 202
TABLE 230 LATIN AMERICA: MACROECONOMIC INDICATORS 203
TABLE 231 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 204
TABLE 232 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2023–2031 (USD MILLION) 204
TABLE 233 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2023–2031 (USD MILLION) 204
TABLE 234 LATIN AMERICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY TYPE,
2023–2031 (USD MILLION) 205
TABLE 235 LATIN AMERICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2031 (USD MILLION) 205
TABLE 236 LATIN AMERICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2023–2031 (USD MILLION) 206
TABLE 237 MIDDLE EAST & AFRICA: MACROINDICATORS 207
TABLE 238 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 207
TABLE 239 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2031 (USD MILLION) 208
TABLE 240 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2031 (USD MILLION) 208
TABLE 241 MIDDLE EAST & AFRICA: SYSTEMIC AUTOIMMUNE DISEASES MARKET,
BY TYPE, 2023–2031 (USD MILLION) 209
TABLE 242 MIDDLE EAST & AFRICA: ORGAN-SPECIFIC AUTOIMMUNE DISEASES MARKET,
BY TYPE, 2023–2031 (USD MILLION) 209
TABLE 243 MIDDLE EAST & AFRICA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031 (USD MILLION) 210
TABLE 244 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET, JANUARY 2021–MAY 2025 211
TABLE 245 AUTOIMMUNITY DIAGNOSTICS MARKET: DEGREE OF COMPETITION 214
TABLE 246 AUTOIMMUNITY DIAGNOSTICS MARKET: REGION FOOTPRINT 218
TABLE 247 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 219
TABLE 248 AUTOIMMUNITY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT 219
TABLE 249 AUTOIMMUNITY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT 220
TABLE 250 AUTOIMMUNITY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 222
TABLE 251 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY PRODUCT AND DISEASE TYPE 222
TABLE 252 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 223
TABLE 253 AUTOIMMUNITY DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 225
TABLE 254 AUTOIMMUNITY DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MAY 2025 225
TABLE 255 AUTOIMMUNITY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MAY 2025 226
TABLE 256 AUTOIMMUNITY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–MAY 2025 226
TABLE 257 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 227
TABLE 258 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 228
TABLE 259 ABBOTT LABORATORIES: COMPANY OVERVIEW 230
TABLE 260 ABBOTT LABORATORIES: PRODUCTS OFFERED 231
TABLE 261 REVVITY, INC.: COMPANY OVERVIEW 233
TABLE 262 REVVITY, INC.: PRODUCTS OFFERED 234
TABLE 263 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 236
TABLE 264 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 238
TABLE 265 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 239
TABLE 266 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2021–MAY 2025 240
TABLE 267 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2025 241
TABLE 268 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS,
JANUARY 2021−MAY 2025 241
TABLE 269 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 243
TABLE 270 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 244
TABLE 271 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2021– MAY 2025 245
TABLE 272 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– MAY 2025 246
TABLE 273 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 248
TABLE 274 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 249
TABLE 275 GRIFOLS S.A.: COMPANY OVERVIEW 251
TABLE 276 GRIFOLS S.A.: PRODUCTS OFFERED 252
TABLE 277 GRIFOLS S.A.: DEALS, JANUARY 2021– MAY 2025 253
TABLE 278 WERFEN S.A.: COMPANY OVERVIEW 254
TABLE 279 WERFEN S.A.: PRODUCTS OFFERED 255
TABLE 280 WERFEN S.A.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 257
TABLE 281 EXAGEN INC.: COMPANY OVERVIEW 258
TABLE 282 EXAGEN INC.: PRODUCTS OFFERED 259
TABLE 283 EXAGEN INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 260
TABLE 284 EXAGEN INC.: DEALS, JANUARY 2021–MAY 2025 260
TABLE 285 TRINITY BIOTECH PLC: COMPANY OVERVIEW 261
TABLE 286 TRINITY BIOTECH PLC: PRODUCTS OFFERED 263
TABLE 287 TECAN GROUP LTD.: COMPANY OVERVIEW 264
TABLE 288 TECAN GROUP LTD.: PRODUCTS OFFERED 265
TABLE 289 DANAHER CORPORATION: COMPANY OVERVIEW 267
TABLE 290 DANAHER CORPORATION: PRODUCTS OFFERED 269
TABLE 291 DANAHER CORPORATION: DEALS, JANUARY 2021– MAY 2025 269
TABLE 292 BIOSYNEX SA: COMPANY OVERVIEW 270
TABLE 293 BIOSYNEX SA: PRODUCTS OFFERED 271
TABLE 294 BIOSYNEX SA: DEALS, JANUARY 2021– MAY 2025 272
TABLE 295 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 273
TABLE 296 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 274
TABLE 297 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021– MAY 2025 275
TABLE 298 BIOMÉRIEUX SA: COMPANY OVERVIEW 276
TABLE 299 BIOMÉRIEUX SA: PRODUCTS OFFERED 277
TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW 278
TABLE 301 DIASORIN S.P.A.: PRODUCTS OFFERED 280
TABLE 302 DIASORIN S.P.A.: DEALS, JANUARY 2021– MAY 2025 280
TABLE 303 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 281
TABLE 304 SD BIOSENSOR, INC.: COMPANY OVERVIEW 282
TABLE 305 CAMBRIDGE LIFE SCIENCES LTD.: COMPANY OVERVIEW 283
TABLE 306 A. MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW 284
TABLE 307 SEBIA: COMPANY OVERVIEW 285
TABLE 308 KRONUS: COMPANY OVERVIEW 286
TABLE 309 ERBA GROUP: COMPANY OVERVIEW 287
TABLE 310 AESKU.GROUP GMBH: COMPANY OVERVIEW 288
TABLE 311 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW 289
TABLE 312 EPITOPE DIAGNOSTICS INC.: COMPANY OVERVIEW 290
LIST OF FIGURES
FIGURE 1 MARKET SEGMENTATION & REGIONAL SCOPE 29
FIGURE 2 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH DESIGN 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 38
FIGURE 4 BREAKDOWN OF PRIMARIES 39
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 7 AUTOIMMUNITY DIAGNOSTICS MARKET: TOP-DOWN APPROACH 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 43
FIGURE 9 AUTOIMMUNITY DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 44
FIGURE 10 AUTOIMMUNITY DIAGNOSTICS MARKET, BY PRODUCT,
2025 VS. 2031 (USD MILLION) 46
FIGURE 11 AUTOIMMUNITY DIAGNOSTICS MARKET, BY TEST TYPE,
2025 VS. 2031 (USD MILLION) 47
FIGURE 12 AUTOIMMUNITY DIAGNOSTICS MARKET, BY DISEASE TYPE,
2025 VS. 2031 (USD MILLION) 47
FIGURE 13 AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER,
2025 VS. 2031 (USD MILLION) 48
FIGURE 14 AUTOIMMUNITY DIAGNOSTICS MARKET, BY REGION,
2025 VS. 2031 (USD MILLION) 49
FIGURE 15 RISING PREVALENCE OF AUTOIMMUNE DISEASES AND INCREASING ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TO PROPEL MARKET 50
FIGURE 16 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51
FIGURE 17 AUTOANTIBODIES AND IMMUNOLOGIC TESTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51
FIGURE 18 SYSTEMIC AUTOIMMUNE DISEASES SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 52
FIGURE 19 CLINICAL LABORATORIES SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 52
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 53
FIGURE 21 AUTOIMMUNITY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 22 PATENT ANALYSIS FOR IMMUNOASSAYS (JANUARY 2014–DECEMBER 2024) 63
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING ASSEMBLY PHASES 65
FIGURE 24 AUTOIMMUNITY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 66
FIGURE 25 AUTOIMMUNITY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 26 AUTOIMMUNITY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 72
FIGURE 28 KEY BUYING CRITERIA FOR AUTOIMMUNITY DIAGNOSTICS PRODUCTS 73
FIGURE 29 AUTOIMMUNITY DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS
IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES IN AUTOIMMUNITY
DIAGNOSTICS MARKET 84
FIGURE 31 MARKET POTENTIAL OF AI IN AUTOIMMUNITY DIAGNOSTICS MARKET 86
FIGURE 32 NORTH AMERICA: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT 149
FIGURE 33 ASIA PACIFIC: AUTOIMMUNITY DIAGNOSTICS SNAPSHOT 183
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY
DIAGNOSTICS MARKET (2022–2024) 213
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOIMMUNITY DIAGNOSTICS MARKET (2024) 214
FIGURE 36 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 217
FIGURE 37 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY FOOTPRINT 218
FIGURE 38 AUTOIMMUNITY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 221
FIGURE 39 EV/EBITDA OF KEY VENDORS 223
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 224
FIGURE 41 AUTOIMMUNITY DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS 224
FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 228
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024) 231
FIGURE 44 REVVITY, INC.: COMPANY SNAPSHOT (2024) 234
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 239
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 244
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 249
FIGURE 48 GRIFOLS S.A.: COMPANY SNAPSHOT (2024) 252
FIGURE 49 WERFEN S.A: COMPANY SNAPSHOT (2024) 255
FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2024) 258
FIGURE 51 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2023) 262
FIGURE 52 TECAN GROUP LTD.: COMPANY SNAPSHOT (2024) 265
FIGURE 53 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 268
FIGURE 54 BIOSYNEX SA: COMPANY SNAPSHOT (2024) 270
FIGURE 55 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 274
FIGURE 56 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2024) 277
FIGURE 57 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024) 279
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11